AUP Aurinia Pharmaceuticals Inc.

Aurinia to Participate in Jefferies London Healthcare Conference

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024.

Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM GMT/7:00 AM EST. This session will not include a webcast.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).

EN
14/11/2024

Underlying

AUPAurinia Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aurinia Pharmaceuticals Inc.

 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia Presents New Data Underscoring Critical Importance of Earlier ...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE), and reinforce the clinical importance of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adults with active...

6h / 46m 1 EN
 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia to Participate in Jefferies London Healthcare Conference

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM GMT/7:00 AM EST. This session will not include a webcast. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to peo...

November 14, 2024 1 EN
 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors t...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry. He previously served as a director of Ardea Biosciences, Inc., Adamis Pharmaceuticals Corporation, Decipher Biosciences, Inc., La Jolla Pharmaceutical Company, Odonate Therapeutics, Inc. and Mirati The...

November 7, 2024 1 EN
 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Fin...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months ended September 30, 2024. With continued strong commercial execution, the Company achieved significant year-over-year growth in total net revenue and net product revenue and $17.0 million in cash flow from operations in the third quarter. Having achieved $158.6 million in net product revenue for the nine months ended September 30, 2024, the Company is reiterating its net product revenue guidance range...

November 7, 2024 1 EN
 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operati...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024. Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. Webcast & Conference Call Details The link to the audio webcast is available . To join the conference call, please dial (800) 715-9871 / +1 (646) 307-1963. Conference ID: 6251719 o...

October 30, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch